INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2021

The US FDA has approved 8 NDAs and 1 BLAs in Dec 2021, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 50 novel products in 2021 In the year 2021, the major highlights were oncology drugs in which 12 out of 50 has approved in oncology,…

January 27, 2022

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2022 Based on Therapeutic Areas

Shots: The 40th Annual J.P. Morgan Healthcare Conference took place virtually on Jan 10-13, 2022. The premier conference is the most extensive and most informative health care investment symposium in the Healthcare and pharma sector, which connects global leaders, emerging companies, innovative technology creators, and members of the investment community Considering the top biopharma companies…

January 19, 2022

Deal Maker of the Year 2021 (Part 02)

Shots: Roche was at the top with 32 deals for a total announced deal value of ~$25.83B with multiple biopharma companies The highest value deal was Roche’s AI pact with Recursion valued at up to ~$12B to identify and develop up to 40 new medications in neuroscience and oncology indications Pfizer and Merck are two…

January 13, 2022

Deal Maker of the Year 2021 (Part 01)

Shots: AstraZeneca and Roche were the top dealmakers completed 33 deals with multiple pharma and biotech companies and universities for a total deal value of $6.2B & $25.83B The highest value deal was AstraZeneca’s partnership with Ionis for the development and commercialization of Eplontersen signed on Dec. 7, 2021. Merck and Pfizer are among the…

January 7, 2022

Insights+ Key Biosimilars Events of December 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of December, Samsung Bioepis presented five-year follow-up results of…

January 6, 2022

Insights+: The US FDA New Drug Approvals in November 2021

The US FDA has approved 6 NDAs and 1 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 68 novel products in 2021 Additionally, last year in 2020, the US FDA…

December 16, 2021

Insights+ Key Biosimilars Events of November 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of November, Bio-Thera Solutions reported the NMPA's acceptance of…

December 2, 2021

Insights+: The US FDA New Drug Approvals in October 2021

The US FDA has approved 4 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 61 novel products in 2021 Additionally, last year in 2020, the US FDA…

November 18, 2021

Insights+ Key Biosimilars Events of October 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of October, Bio-Thera expanded its partnership with Pharmapark to…

November 11, 2021

Insights+: The US FDA New Drug Approvals in September 2021

The US FDA has approved 5 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 55 novel products in 2021 Additionally, last year in 2020, the US FDA…

October 21, 2021